(3R,4S,5S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-4-methyl-6-oxoheptanal | 1207735-02-1

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: (3R,4S,5S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-4-methyl-6-oxoheptanal
• 英文别名: (3R,4S,5S)-3,5-bis[[tert-butyl(dimethyl)silyl]oxy]-4-methyl-6-oxoheptanal
• CAS: 1207735-02-1
• 化学式: C₂₀H₄₂O₄Si₂
• 分子量: 402.722
• InChiKey: BWAYFAGVUFWRQP-JQHSSLGASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.58
• 重原子数：
  26
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  四溴化碳 、 (3R,4S,5S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-4-methyl-6-oxoheptanal 在 三苯基膦 、 锌 作用下， 以 二氯甲烷 为溶剂， 反应 2.83h， 以75%的产率得到(3S,4S,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-8,8-dibromo-4-methyloct-7-en-2-one
  参考文献：
  名称：

  Structure−Function Relationships and Crystal Structures of the Vitamin D Receptor Bound 2α-Methyl-(20S,23S)- and 2α-Methyl-(20S,23R)-epoxymethano-1α,25-dihydroxyvitamin D₃

  摘要：

  The vitamin D nuclear receptor is a ligand-dependent transcription factor that controls multiple biological responses such as cell proliferation, immune responses, and bone mineralization. Numerous 1 alpha,25(OH)(2)D-3 analogues, which exhibit low calcemic side effects and/or antitumoral properties, have been synthesized. We recently showed that the synthetic analogue (20S,23S)-epoxymethano-1 alpha,25-dihydroxyvitamin D-3 (2a) acts as a 1 alpha,25(OH)(2)D-3 superagonist and exhibits both antiproliferative and prodifferentiating properties in vitro. Using this information and on the basis of the crystal structures of human VDR ligand binding domain (hVDR LBD) bound to 1 alpha,25(OH)(2)D-3,2 alpha-methyl-1 alpha,25(OH)(2)D-3, or 2a, we designed a novel analogue, 2 alpha-methyl-(20S,23S)-epoxymethano-1 alpha,25-dihydroxyvitamin D-3 (4a), in order to increase its transactivation potency. Here, we solved the crystal structures of the hVDR LBD in complex with the 4a (C23S) and its epimer 4b (C23R) and determined their correlation with specific biological outcomes.

  DOI：

  10.1021/jm9014636
• 作为产物：
  描述：

  (1S,2S,3R,4R,6R)-2,4-bis[(tert-butyldimethylsilyl)oxy]-1,3-dimethyl-7-oxabicyclo[4.1.0]heptane 在 高碘酸 作用下， 以 乙醚 为溶剂， 反应 12.0h， 以1.56 g的产率得到(3R,4S,5S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-4-methyl-6-oxoheptanal
  参考文献：
  名称：

  Structure−Function Relationships and Crystal Structures of the Vitamin D Receptor Bound 2α-Methyl-(20S,23S)- and 2α-Methyl-(20S,23R)-epoxymethano-1α,25-dihydroxyvitamin D₃

  摘要：

  The vitamin D nuclear receptor is a ligand-dependent transcription factor that controls multiple biological responses such as cell proliferation, immune responses, and bone mineralization. Numerous 1 alpha,25(OH)(2)D-3 analogues, which exhibit low calcemic side effects and/or antitumoral properties, have been synthesized. We recently showed that the synthetic analogue (20S,23S)-epoxymethano-1 alpha,25-dihydroxyvitamin D-3 (2a) acts as a 1 alpha,25(OH)(2)D-3 superagonist and exhibits both antiproliferative and prodifferentiating properties in vitro. Using this information and on the basis of the crystal structures of human VDR ligand binding domain (hVDR LBD) bound to 1 alpha,25(OH)(2)D-3,2 alpha-methyl-1 alpha,25(OH)(2)D-3, or 2a, we designed a novel analogue, 2 alpha-methyl-(20S,23S)-epoxymethano-1 alpha,25-dihydroxyvitamin D-3 (4a), in order to increase its transactivation potency. Here, we solved the crystal structures of the hVDR LBD in complex with the 4a (C23S) and its epimer 4b (C23R) and determined their correlation with specific biological outcomes.

  DOI：

  10.1021/jm9014636

文献信息

• Structure−Function Relationships and Crystal Structures of the Vitamin D Receptor Bound 2α-Methyl-(20<i>S</i>,23<i>S</i>)- and 2α-Methyl-(20<i>S</i>,23<i>R</i>)-epoxymethano-1α,25-dihydroxyvitamin D₃
  作者：Pierre Antony、Rita Sigüeiro、Tiphaine Huet、Yoshiteru Sato、Nick Ramalanjaona、Luis Cezar Rodrigues、Antonio Mouriño、Dino Moras、Natacha Rochel

  DOI：10.1021/jm9014636

  日期：2010.2.11

  The vitamin D nuclear receptor is a ligand-dependent transcription factor that controls multiple biological responses such as cell proliferation, immune responses, and bone mineralization. Numerous 1 alpha,25(OH)(2)D-3 analogues, which exhibit low calcemic side effects and/or antitumoral properties, have been synthesized. We recently showed that the synthetic analogue (20S,23S)-epoxymethano-1 alpha,25-dihydroxyvitamin D-3 (2a) acts as a 1 alpha,25(OH)(2)D-3 superagonist and exhibits both antiproliferative and prodifferentiating properties in vitro. Using this information and on the basis of the crystal structures of human VDR ligand binding domain (hVDR LBD) bound to 1 alpha,25(OH)(2)D-3,2 alpha-methyl-1 alpha,25(OH)(2)D-3, or 2a, we designed a novel analogue, 2 alpha-methyl-(20S,23S)-epoxymethano-1 alpha,25-dihydroxyvitamin D-3 (4a), in order to increase its transactivation potency. Here, we solved the crystal structures of the hVDR LBD in complex with the 4a (C23S) and its epimer 4b (C23R) and determined their correlation with specific biological outcomes.